Quantcast

Argos Therapeutics to Present About the Implementation, Cost Effectiveness and Benefits of Automation for its Arcelis(TM) Immunotherapy at The Cell Therapy Industry Summit-2010

November 2, 2010

DURHAM, N.C., Nov. 2, 2010 /PRNewswire/ — Argos Therapeutics today announced that Fred Miesowicz, the company’s chief operating officer and vice president of manufacturing, will present on the implementation, cost effectiveness and benefits of automation for Argos’ Arcelis(TM) immunotherapy at The Cell Therapy Industry Summit-2010 in Carlsbad, Calif. at 2 p.m. PDT on Thursday, Nov. 4. The conference will take place at the Sheraton Carlsbad Resort & Spa.

Argos recently announced positive interim results from a Phase 2 clinical study of its Arcelis(TM) immunotherapy in combination with sunitinib, for the treatment of renal cell carcinoma (RCC). The company plans to move forward with a Phase 3 clinical trial and implement its automation process prior to commercialization. This will provide Argos with the potential to immediately address the medical needs of the entire targeted RCC patient population.

About the Arcelis(TM) Technology

Arcelis is Argos’ proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient’s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient’s disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA (“mRNA”) isolated from the patient’s disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient’s specific disease.

About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com


    Contacts:
    ---------

    David Schull or Andreas Marathovouniotis
    Russo Partners LLC
    (212) 845-4271 or (212) 845-4235
    david.schull@russopartnersllc.com or
     andreas.marathis@russopartnersllc.com

    Jeff Abbey
    Argos Therapeutics
    (919) 287-6308
    jabbey@argostherapeutics.com

SOURCE Argos Therapeutics, Inc.


Source: newswire



comments powered by Disqus